#41 – H5N1: Why Avian Influenza Is Dangerous Again
H5N1 avian influenza is back in the headlines, and on two fronts at once. Florian Krammer starts with the basics: why the subtype is named after its two spike proteins, hemagglutinin and neuraminidase, what separates highly pathogenic from low pathogenic strains, and why the virus still does not spread from human to human. The answer lies in the receptors, since avian strains bind alpha-2,3-linked sialic acid, which in humans is found deep in the lung but not in the upper respiratory tract. Since 1997 there have been around 900 human cases, roughly half of them fatal. Since 2020 the clade 2.3.4.4b variant has spread worldwide and shows a striking tendency to infect mammals. In 2024 it turned up unexpectedly in US dairy cattle, where it replicates in the mammary glands and spreads between cows through unsanitized milking equipment. An active outbreak in Washington State's Yakima Valley has now caused three human infections, one of them fatal, and a farm worker union reports further cases among people who avoid testing out of fear of immigration enforcement. On top of that, a mink farm outbreak in Utah has been running uncontrolled since August. The core concern: if someone is infected with seasonal flu and H5N1 at the same time, the viruses can swap genomic segments. That is exactly how the last influenza pandemics began. Report about the cattle outbreak in Washington State: https://www.cidrap.umn.edu/avian-influenza-bird-flu/oregon-logs-its-first-h5n1-case-cows-farmer-s-union-says-human-avian-flu Detailed report about the mink outbreak in Utah: https://www.propublica.org/article/bird-flu-mink-farm-utah-human-risk Farm Workers Union statement about human H5N1 infections on Twitter: https://x.com/UFWupdates/status/2120328692589355089 +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
- Transcript